Πηγή: FiercePharma
The names at the very top of our yearly list of biggest pharma companies
are no surprise. Johnson & Johnson ($JNJ), Novartis ($NVS), Roche ($RHHBY) and Pfizer ($PFE) have headed up the rankings for a couple of years now, albeit in varying
order. But toward the bottom of the top 10, there's been a changing of the
guard.
For the first time, a biotech company has nudged aside one of the biggest
Big Pharma names. Eli Lilly & Co. ($LLY), which hung onto 10th place last year by its fingernails, is now out of
the top 10, replaced by Gilead Sciences ($GILD) and its skyrocketing sales. Fueled by its brand-new blockbuster hepatitis
C drug, Sovaldi, Gilead revenue more than doubled last year, to $24.5 billion
from $10.8 billion.
The rest of the top 10 are the usual suspects--Sanofi ($SNY), Merck ($MRK), GlaxoSmithKline ($GSK), AstraZeneca ($AZN) and Bayer HealthCare. They're in slightly different slots for 2014, but all present and
accounted for.